Cambridge Cognition in deal with Pfizer and Eisai

27 June 2004

The UK's Cambridge Cognition says it has signed a co-marketing deal with US drug major Pfizer and Eisai UK for its CANTAB cognitive screening tests, which provide early detection and diagnosis of Alzheimer's disease and other types of dementia. Notably, they can differentiate between memory loss caused by dementia and that caused by depression which is often confused with dementia, according to Cambridge Cognition.

This will be the first time that the CANTAB tests will be widely available through the UK's National Health Service, although there have been a number of successful trials in both memory clinics and general practice surgeries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight